Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-titration study of KER-047 in functional iron deficiency anemia associated with MDS, myelofibrosis, and MDS/MPN overlap syndromes
MOH_2022-08-27_011857Phase 2Completed
- Sponsor
- Keros Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of KER-047 in iron deficiency anemia (IDA) (2 arms), sponsored by Keros Therapeutics. Primary endpoints: Safety and tolerability of response-guided KER-047 dose titration, Pharmacokinetics of KER-047 and 2 more. Started Apr 2022; status: completed.
02
Drugs
KER-047
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on MOH_2022-08-27_011857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-27_011857.